Drug – bio-affecting and body treating compositions – Effervescent or pressurized fluid containing – Organic pressurized fluid
Reexamination Certificate
2007-04-24
2007-04-24
Richter, Johann (Department: 1616)
Drug, bio-affecting and body treating compositions
Effervescent or pressurized fluid containing
Organic pressurized fluid
C424S046000, C424S489000, C514S002600, C128S203150
Reexamination Certificate
active
10654815
ABSTRACT:
A method and a composition for treatment of pulmonary bacterial infections caused by gram-negative bacteria suitable for treatment of infection caused byEscherichia coli, Klebsiella pneumoniae, Klebsiella oxytoca, Pseudomonas aeruginosa, Haemophilus influenzae, Proteus mirabilis, Enterobacterspecies,Serratia marcescensas well as those caused byBurkholderia cepacia, Stenotrophomonas maltophilia, Alcaligenes xylosoxidans, and multidrug resistantPseudomonas aeruginosa, using a concentrated formulation of aztreonam, or a pharmaceutically acceptable salt thereof, delivered as an aerosol or dry powder formulation.
REFERENCES:
patent: 4550105 (1985-10-01), Matsuo et al.
patent: 4572801 (1986-02-01), Matsuo, deceased et al.
patent: 4610824 (1986-09-01), Truner
patent: 4673739 (1987-06-01), Matsuo, deceased et al.
patent: 4775670 (1988-10-01), Sykes et al.
patent: 4946838 (1990-08-01), Floyd et al.
patent: 5662929 (1997-09-01), Lagace et al.
patent: 5875776 (1999-03-01), Vaghefi
patent: 6518239 (2003-02-01), Kuo et al.
patent: 2004/0009126 (2004-01-01), Pilkiewicz et al.
patent: 2004/0062721 (2004-04-01), Montgomery
patent: 02975801 (1999-01-01), None
patent: WO 0134232 (2001-05-01), None
Despina Daisy Frangolias, et al.,Burkholderia cepaciain Cystic Fibrosis,Am. J or Respir Crit Care Med. 160:1572-1577 (1999).
Diane H. Johnson, et al., Aztreonam,Medical Clinics of North America, 79/4:733-743 (Jul. 4, 1995).
Woo, M.S., et al., Use of Aersolized Aztreonam in CF Lung Transplant Pateints Colonized WithBurkholderia cepacia, 2002 Cystic Fibrosis Conference, p. 322:419.
Petra Borsje, MD, et al., Aerosol Therapy in Cystic Fibrosis: A Survey of 54 CF Centers,Pediatric Pulmonology, 30:368-376 (2000).
Rafael Canton, PD, PhD, et al., Lung Colonization WithEnterobacteriaceaeProducing Extended-Spectrum β-Lactamases in Cystic Fibrosis Patients,Pediatric Pulmonology, 24:213-217 (1997).
S. Ballestero, et al.,Stenocrophomonas maltiphiliain Cystic Fibrosis Patients, p. 12, 20thEuropean Cystic Fibrosis Conference, Brussels, Belgium, (Jun. 18-21, 1995).
Sira Carrasco, et al., The General Approach to Cystic Fibrosis Pulmonary Infection in Spain,Cystic Fibrosis Pulmonary Infections: Lessons From Around the World, Chapter 18, pp. 223-230 (1996).
Brian E. Scully, M.B., et al., Use of Aztreonam in the Treatment of Serious Infections Due to Multiresistant Gram-Negative Organisms, IncludingPseudomonas Aeruginosa, The American Journal of Medicine, 78:251-261 (Feb. 1985).
John A. Bosso, et al., Efficacy of Aztreonam in Pulmonary Exacerbations of Cystic Fibrosis,The Pediatr. Infect. Dis. J., 6:393-397 (1987).
James L. Cook, M.D., Gram-Negative Bacillary Pneumonia in the Nosocomial Setting,The American Journal of Medicine, 88:3C-34S-37S.
A. Boccazzi, et al., The Pharmacokinetics of Aztreonam and Penetration into the Bronchial Secretions of Critically Ill Patients,Journal of Antimicrobial Chemotherapy, 23:401-407, (1989).
Harold C. Neu, M.D., Aztreonam Activity, Pharmacology and Clinical Uses,The American Journal of Medicine, 88:3C-2S-3C-6S.
John J. LiPuma, MD,Burkholderia cepacia, Management Issues and New Insights,Clinics in Chest Medicine, 19/3:473-486 (Sep. 1998).
Stephen C. Aronoff, et al.,In VitroActivities of aztreonam, Piperacillin, and Ticarcillin Combined with Amikacin Against Amikacin-ResistantPseudomonas aeruginosaandP. cepaciaIsolates from Children with Cystic Fibrosis,Antimicrobial Agents and Chemotherapy, 25/2:279-280 (Feb. 1984).
John A. Bosso, et al.,In VitroAcitivities of Combinations of Aztreonam, Ciprofloxacin, and Ceftazidime Against Clinical Isolates ofPseudomonas aeruoginosaandPseudomonas cepaciafrom Patients with Cystic Fibrosis,Antimicrobial Agents and Chemotherapy, 34/3:487-488 (Mar. 1990).
John M. Matsen, et al., The Use of Aztreonam in the Cystic Fibrosis Patient,Pediatr. Infect. Dis. J., 8/9:S117-S119 (1989).
Lisa Saiman, MD, Antimicrobial Resistance AmongBurkholderia stenotrophomonasand Alcaligenes isolates Studied by the CF Eferal Center for Susceptibility and Synergy Testing, 1998 Cystic Fibrosis Conference, Symposium Session Summaries, 118-119 (1998).
Preston W. Campbell III, MD., et al., Use of Aerosolled Antibiotics in Patients with Cystic Fibrosis, Consensus Conference, pp. 775-789 (Sep. 1999).
Dapena Fernandez J., et al., Inhaled Aztreonam Therapy in Patients with Cystic Fibrosis Colonized withPseudomonas aeruginosa, Spanish Annals on Pediatrics, 40/3 (1993).
Corus Pharma, Inc.
Haghighatian Mina
Peters Verny LLP
Richter Johann
Verny Hana
LandOfFree
Inhalable aztreonam aerosol for treatment and prevention of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Inhalable aztreonam aerosol for treatment and prevention of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inhalable aztreonam aerosol for treatment and prevention of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3790175